Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 36:916-921, Adams,H.,et al, 2005
Guidelines for the Management of Patients with Acute Ischemic Stroke
Stroke 25:1901-1914, Adams,H.P.,et al, 1994
Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase LLB Study
Lancet 372:1463-1472, Kappos,L.,et al, 2008
Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006
Calcium Antagnosits in Aneurysmal Subarachnoid Hemorrhage
Stroke 36:1816-1817, Rinkel,G.J.E.,et al, 2005
Neuroprotection in Parkinson Disease, Mysteries, Myths, and Misconceptions
JAMA 291:358-364, Schapira,A.H.V.&Olanow,C.W., 2004
[123I]b-CIT SPECT is a Useful Method for Monitoring Dopaminergic Degeneration in Early Stage Parkinson's Disease
JNNP 74:294-298,287, Winogrodzka,A.,et al, 2003
Evidence for Widespread Axonal Damage at the Earliest Clinical Stage of Multiple Sclerosis
Brain 126:433-437, Filippi,M.,et al, 2003
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 34:1056-1083, Adams,H.P.,et al, 2003
New Imaging Strategies for Patient Selection for Thrombolytic and Neuroprotective Therapies
Neurol 57:S48-S52, Warach,S., 2001
Ischemic Core and Penumbra in Human Stroke
Stroke 30:93-99, Kaufmann,A.M.,et al, 1999
Progression of Ischaemic Stroke and Excitotoxic Aminoacids
Lancet 349:79-83, Castillo,J.,et al, 1997
Characterizing the Target of Acute Stroke Therapy
Stroke 28:866-872, Fisher,M., 1997
Head Injury
JNNP 56:440-447, Miller,J.D., 1993